Health Care • Biotechnology: Pharmaceutical Preparations
$41.24 ▼ -2.28
(-5.24%)
MKT CAP: $7.23B • VOL: 2.56M
52W L $42 52W H $87
IONS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $943.7M | $705.1M | $787.6M |
| YoY Revenue Growth % | +33.8% | -10.5% | — |
| Gross Profit | $927.8M | $693.9M | — |
| Gross Margin % | 98.3% | 98.4% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$381.7M | -$475.1M | -$353.7M |
| Operating Margin % | -40.4% | -67.4% | -44.9% |
| Net Income (GAAP) | -$381.4M | -$453.9M | -$366.3M |
| EBITDA (Normalized) | -$340.5M | -$438.9M | -$325.4M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$268.6M | -$500.9M | -$307.5M |
| Capital Expenditures (CapEx) | $51.4M | $45.3M | $35.4M |
| Free Cash Flow (FCF) | -$320.0M | -$546.2M | -$343.0M |
| FCF Margin % | -33.9% | -77.5% | -43.5% |
| Return on Invested Capital (ROIC %) | -20.9% | -24.2% | -11.4% |
| Cash & Short-Term Equivalents | $372.3M | $242.1M | — |
| Total Debt (Short + Long Term) | $1.33B | $1.20B | $949.4M |
| Total Stockholders' Equity | $489.1M | $588.4M | $1.95B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IONS.